Jianfeng Group Pro 2015-007 (Jianfeng Group Daily Related Party Transaction Announcement)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-007
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Regular Related Party Transaction Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Basic Information of 1. Daily Related Party Transactions
Review Procedures for Implementation of (I) Daily Related Party Transactions
Jinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Pharmaceutical Company") purchases drugs from related party Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd. (hereinafter referred to as "Tianshili Marketing Group"). It is estimated that the purchase amount in 2015 will be between 0.5 and 5% of the company's audited net assets at the end of 2014 (no more than 103.0351 million yuan). Therefore, this related party transaction needs to be submitted to the board of directors for deliberation, but does not need to be submitted to the general meeting of shareholders for deliberation.
On April 17, 2015, the company held the second meeting of the ninth board of directors. All nine directors of the company attended the meeting in person. The related directors Mr. Jiang Xiaomeng and Mr. Du Zihong avoided voting on the proposal, which complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and effective. After deliberation and voting, the board of directors deliberated and passed the daily related party transaction proposal with 7 votes in favor, 0 votes against and 0 abstention.
The independent directors of the company reviewed the matter in advance and agreed to submit the proposal to the second meeting of the ninth board of directors of the company for deliberation. The independent directors of the company expressed their independent opinions on the adoption of the proposal by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.
Forecast and Implementation of (II)'s Last Daily Related Party Transaction
The Company issued a public announcement on April 15, 2014. It is estimated that the amount of drugs purchased by Jinhua Pharmaceutical Company from Tianshili Marketing Group in 2014 will be between 0.5 and 5% (between 8.685 million yuan and 86.8499 million yuan) of the Company's audited net assets at the end of 2013. The actual amount incurred in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions, which did not exceed the expected range.
2. Related Party Introduction and Association Relationship
(I) the basic situation of related parties.
1. Jinhua Pharmaceutical Company: Established in January 1994, its domicile is located at 1180 Huancheng East Road, Jinhua City, its legal representative is Jin Xuecai, and its registered capital is 22 million yuan, of which: the company accounts for 10%, Zhejiang Jianfeng Pharmaceutical Co., Ltd., its holding subsidiary, accounts for 90%, and its main business is drug management. Wholesale and retail of prepackaged food; dangerous chemicals and medical devices; chemical reagents (except dangerous goods); glass and products; textiles, clothing and household daily necessities (except dangerous goods); fitness equipment supplies; computers, software and auxiliary equipment; wholesale and retail of teaching molds; exhibition services; medical information services; branches operate with valid certificates: purchase and processing of traditional Chinese medicine. The drug business license mainly includes: sales of proprietary Chinese medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. The audited net profit for 2014 was 6.5056 million yuan, the net assets at the end of 2014 was 73.169 million yuan, and the liabilities were 237.9614 million yuan.
2, Tianshili Marketing Group: The company was established in 1999 February. The company's domicile is Tianshili Modern Chinese Medicine City, Xinyibai Avenue, Beichen Science and Technology Park, Tianjin, with its legal representative Yan Kaijing and registered capital of 25900 yuan, the business scope is the wholesale of Chinese herbal pieces, Chinese medicinal materials, Chinese patent medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, biological products, and diagnostic drugs; chemical raw materials ( except hazardous chemicals and precursor drugs ) , Wholesale and retail of cosmetics, daily chemical products, packaging materials and containers, plastic products, molds, and plastic raw materials; health food (hard capsules, soft capsules, granules, tablets, oral liquids, tea bags, health wine) wholesale and retail; disposable sterile syringes (needles), infusion sets (needles), corneal contact lenses and nursing solutions, medical polymer materials and products, physical therapy and rehabilitation equipment, medical hygiene materials and dressings, Chinese medicine equipment, general diagnosis equipment, Ward care equipment and appliances, household blood glucose meters and test strips, pregnancy diagnosis test strips, condoms wholesale; self-employed and agent of all kinds of goods and technology import and export business, but the state restricts the company to operate or prohibits the import and export of goods and technology, operating feed processing and "three to one supplement " business, operating trade and re-export trade, pre-packaged food wholesale and retail. The net profit attributable to the parent company in 2014 was 16,080.14 yuan, The net assets attributable to the parent company at the end of 2014 were 9,234.05 yuan, and the liabilities were 482,239.84 yuan.
The relationship between the (II) and the listed company
Because Tianshili Marketing Group is the holding subsidiary of Tianshili Pharmaceutical Group Co., Ltd., and Tianshili Pharmaceutical Group Co., Ltd. is the holding subsidiary of Tianshili Holding Group Co., Ltd. (hereinafter referred to as "Tianshili Group"), tasly Group is an associate of the Company and the Company has two directors who are also directors of Tasly Group, so Jinhua Pharmaceutical Company is related to Tasly Marketing Group.
(III) The amount of related party transactions in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions. The implementation was good and there were no disputes.
Main Contents and Pricing Policy of 3. Related Party Transaction
Jinhua Pharmaceutical Company plans to continue to purchase drugs from Tianshili Marketing Group for sale this year. The main contents of this related party transaction are as follows:
(1) Transaction Target: Compound Danshen Dripping Pills, Yangxue Qingnao Granules, etc.
(2) Transaction Price: Agreement Price.
(3) settlement method: full payment according to the sales amount of last month.
(4) Agreement Validity Period: The validity period of the agreement signed by the above-mentioned related parties is 1 year from the date of signature by the legal representatives or authorized representatives of both parties.
(5) Other matters: If there is a major change in the content of this related party transaction during the implementation of the agreement, the company will disclose it in accordance with relevant regulations, and investors are requested to pay attention.
Purpose of 4. Related Party Transaction and Impact on Listed Companies
This related party transaction is to use Jinhua Pharmaceutical Company's existing sales network in Zhejiang Province to purchase drugs from Tianshili Marketing Group for distribution and sales, thus expanding Jinhua Pharmaceutical Company's business scope, further enhancing the Company's market influence and enhancing the Company's marketing capability. At the same time, Tasly Marketing Group is an indirect holding subsidiary of the Company's associates, and the expansion of its sales channels has increased the scale of corporate sales. The connected transaction will not harm the interests of the Company or the minority shareholders.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 21, 2015
More information
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-30
Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has
2020
07-31
Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute
A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody
2020
07-31
On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.
2020
07-31
Peak natural products pollution control results by the industry attention
As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.
2020
07-31